34
Participants
Start Date
May 30, 2017
Primary Completion Date
October 31, 2020
Study Completion Date
December 15, 2021
Panitumumab
Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
5Fluorouracil
Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
Oxaliplatin
Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
Leucovorin
Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
Hospital General Universitario de Elche, Elche
Hospital Universitario La Paz, Madrid
Complejo Hospitalario de Navarra, Pamplona
Hospital Universitario Virgen del Rocío, Seville
Fundación Instituto Valenciano de Oncología, Valencia
Consorcio Hospital General Universitario de Valencia, Valencia
Hospital de Sabadell, Sabadell
Hospital de Sant Joan Despí Moisés Broggi, Sant Joan Despí
Hospital de la Santa Creu i Sant Pau, Barcelona
Hospital Universitari Vall d'Hebrón, Barcelona
Hospital Clinic i Provincial, Barcelona
Collaborators (1)
Pivotal S.L.
INDUSTRY
Amgen
INDUSTRY
Grupo Espanol Multidisciplinario del Cancer Digestivo
OTHER